0001209191-19-007770.txt : 20190206
0001209191-19-007770.hdr.sgml : 20190206
20190206164936
ACCESSION NUMBER: 0001209191-19-007770
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190204
FILED AS OF DATE: 20190206
DATE AS OF CHANGE: 20190206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Silva Paul M
CENTRAL INDEX KEY: 0001446372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 19572071
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-04
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001446372
Silva Paul M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
SVP & Interim CFO
Common Stock
2019-02-04
4
M
0
809
86.52
A
16896
D
Common Stock
2019-02-04
4
S
0
809
189.19
D
16087
D
Common Stock
2019-02-04
4
S
0
600
185.11
D
15487
D
Common Stock
2019-02-04
4
S
0
450
186.17
D
15037
D
Common Stock
2019-02-04
4
S
0
2268
186.85
D
12769
D
Common Stock
2019-02-04
4
S
0
120
188.33
D
12649
D
Stock Option (Right to Buy)
86.52
2019-02-04
4
M
0
809
0.00
D
2027-02-02
Common Stock
809
6472
D
Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $185.11 (range $184.54 to $185.49).
Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $186.17 (range $185.74 to $186.52).
Open market sales reported on this line occurred at a weighted average price of $186.85 (range $186.62 to $187.33).
Open market sales reported on this line occurred at a weighted average price of $188.33 (range $188.25 to $188.35).
The option vests in 16 quarterly installments from 02/03/2017.
/s/ Omar White, Attorney-in-Fact
2019-02-06